You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePhenobarbital
Accession NumberDB01174  (APRD00184)
TypeSmall Molecule
GroupsApproved
DescriptionA barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. [PubChem]
Structure
Thumb
Synonyms
5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione
5-Ethyl-5-phenylbarbituric acid
5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
5-Phenyl-5-ethylbarbituric acid
Luminal
Phenobarbital
Phenobarbitol
Phenobarbitone
Phenobarbituric Acid
Phenylaethylbarbitursaeure
Phenylethylbarbiturate
Phenylethylbarbituric Acid
Phenylethylbarbitursaeure
PHENYLETHYLMALONYLUREA
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Barbilixir Elx 4mg/mlelixir4 mgoralD.C. Labs Limited1983-12-312005-07-19Canada
Phenobarbtablet15 mgoralPendopharm Division Of De Pharmascience Inc1957-12-31Not applicableCanada
Phenobarbtablet30 mgoralPendopharm Division Of De Pharmascience Inc1957-12-31Not applicableCanada
Phenobarbtablet60 mgoralPendopharm Division Of De Pharmascience Inc1957-12-31Not applicableCanada
Phenobarbtablet100 mgoralPendopharm Division Of De Pharmascience Inc1957-12-31Not applicableCanada
Phenobarb Elixirelixir5 mgoralPendopharm Division Of De Pharmascience Inc1965-12-31Not applicableCanada
Phenobarbital 100mg Tabtablet100 mgoralValeant Canada Lp Valeant Canada S.E.C.1975-12-312009-07-02Canada
Phenobarbital Sodium Injection 120mg/mlsolution120 mgintramuscular; intravenousHospira Healthcare Corporation1981-12-312012-08-03Canada
Phenobarbital Sodium Injection 30mg/mlsolution30 mgintramuscular; intravenous; subcutaneousHospira Healthcare Corporation1981-12-312012-08-03Canada
Phenobarbital Sodium Injection, USPsolution30 mgintramuscular; intravenousSandoz Canada Incorporated2008-02-29Not applicableCanada
Phenobarbital Sodium Injection, USPsolution120 mgintramuscular; intravenousSandoz Canada Incorporated2008-02-29Not applicableCanada
Phenobarbital Tab 15mgtablet15 mgoralValeant Canada Lp Valeant Canada S.E.C.1962-12-312009-07-02Canada
Phenobarbital Tab 15mgtablet15 mgoralErfa Canada 2012 Inc1951-12-312005-08-12Canada
Phenobarbital Tab 30mgtablet30 mgoralErfa Canada 2012 Inc1951-12-312005-08-12Canada
Phenobarbital Tab 30mgtablet30 mgoralValeant Canada Lp Valeant Canada S.E.C.1962-12-312009-07-02Canada
Phenobarbital Tab 60mgtablet60 mgoralErfa Canada 2012 Inc1951-12-312005-08-12Canada
Phenobarbital Tab 60mgtablet60 mgoralValeant Canada Lp Valeant Canada S.E.C.1974-12-312009-07-02Canada
Phenobarbital Tablet 100mgtablet100 mgoralD.C. Labs Limited1951-12-312003-07-11Canada
Phenobarbital Tablet 15mgtablet15 mgoralD.C. Labs Limited1951-12-312003-07-11Canada
Phenobarbital Tablet 30mgtablet30 mgoralD.C. Labs Limited1951-12-312005-07-19Canada
Phenobarbital Tablet 60mgtablet60 mgoralD.C. Labs Limited1951-12-312005-07-19Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Phenobarbitaltablet64.8 mg/1oralQualitest Pharmaceuticals2001-12-01Not applicableUs
Phenobarbitaltablet16.2 mg/1oralbryant ranch prepack2002-03-01Not applicableUs
Phenobarbitaltablet97.2 mg/1oralE5 Pharma, Llc2016-01-07Not applicableUs
Phenobarbitaltablet30 mg/1oralC.O. Truxton, Inc.2012-03-01Not applicableUs
Phenobarbitaltablet64.8 mg/1oralECI Pharmaceuticals, LLC2014-11-24Not applicableUs
Phenobarbitaltablet97.2 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Phenobarbitaltablet64.8 mg/1oralContract Pharmacy Services Pa2001-12-01Not applicableUs
Phenobarbitaltablet100 mg/1oralWest Ward Pharmaceuticals Corp2012-03-01Not applicableUs
Phenobarbitalliquid20 mg/5mLoralPACK Pharmaceuticals, LLC2011-07-08Not applicableUs
Phenobarbitaltablet32.4 mg/1oralPd Rx Pharmaceuticals, Inc.2003-02-01Not applicableUs
Phenobarbitaltablet16.2 mg/1oralE5 Pharma, Llc2016-01-07Not applicableUs
Phenobarbitalelixir20 mg/5mLoralQualitest Pharmaceuticals1997-01-01Not applicableUs
Phenobarbitaltablet15 mg/1oralWest Ward Pharmaceuticals Corp2012-03-01Not applicableUs
Phenobarbitaltablet97.2 mg/1oralQualitest Pharmaceuticals2001-12-01Not applicableUs
Phenobarbitaltablet16.2 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2007-09-05Not applicableUs
Phenobarbitaltablet97.2 mg/1oralECI Pharmaceuticals, LLC2014-11-24Not applicableUs
Phenobarbitaltablet15 mg/1oralMc Kesson Contract Packaging2012-02-20Not applicableUs
Phenobarbitaltablet60 mg/1oralC.O. Truxton, Inc.2012-03-01Not applicableUs
Phenobarbitaltablet32.4 mg/1oralAphena Pharma Solutions Tennessee, Inc.2003-02-01Not applicableUs
Phenobarbitalelixir20 mg/5mLoralAtlantic Biologicals Corps1997-01-01Not applicableUs
Phenobarbitaltablet64.8 mg/1oralDIRECT RX2014-01-01Not applicableUs
Phenobarbitaltablet32.4 mg/1oralE5 Pharma, Llc2016-01-07Not applicableUs
Phenobarbitaltablet16.2 mg/1oralQualitest Pharmaceuticals2002-03-01Not applicableUs
Phenobarbitaltablet32.4 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2007-07-17Not applicableUs
Phenobarbitaltablet30 mg/1oralWest Ward Pharmaceuticals Corp2012-03-01Not applicableUs
Phenobarbitaltablet16.2 mg/1oralCardinal Health2002-03-01Not applicableUs
Phenobarbitaltablet30 mg/1oralMc Kesson Contract Packaging2011-10-24Not applicableUs
Phenobarbitaltablet15 mg/1oralC.O. Truxton, Inc.2012-03-01Not applicableUs
Phenobarbitaltablet32.4 mg/1oralAmerican Health Packaging2014-08-29Not applicableUs
Phenobarbitaltablet16.2 mg/1oralECI Pharmaceuticals, LLC2014-11-24Not applicableUs
Phenobarbitaltablet32.4 mg/1oralQualitest Pharmaceuticals2003-02-01Not applicableUs
Phenobarbitaltablet15 mg/1oralbryant ranch prepack2000-01-01Not applicableUs
Phenobarbitaltablet64.8 mg/1oralE5 Pharma, Llc2016-01-07Not applicableUs
Phenobarbitaltablet32.4 mg/1oralContract Pharmacy Services Pa2003-02-01Not applicableUs
Phenobarbitaltablet60 mg/1oralWest Ward Pharmaceuticals Corp2012-03-01Not applicableUs
Phenobarbitaltablet32.4 mg/1oralCardinal Health2003-02-01Not applicableUs
Phenobarbitaltablet60 mg/1oralMc Kesson Contract Packaging2011-11-14Not applicableUs
Phenobarbitaltablet100 mg/1oralC.O. Truxton, Inc.2012-03-01Not applicableUs
Phenobarbitaltablet32.4 mg/1oralECI Pharmaceuticals, LLC2014-11-24Not applicableUs
Phenobarbitaltablet64.8 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Phenobarbital Sodiuminjection65 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
Phenobarbital Sodiuminjection130 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
International Brands
NameCompany
LuminalNot Available
Brand mixtures
NameLabellerIngredients
B-donnaWinder Laboratories, LLC
Belladonna Alkaloids With PhenobartbitalLiberty Pharmaceuticals, Inc.
DiclophenPro Doc Limitee
Dilantin W Phenobarbital 15mgParke Davis Division, Warner Lambert Canada Inc.
Dilantin W Phenobarbital 30mg CapParke Davis Division, Warner Lambert Canada Inc.
DonnatalKAISER FOUNDATION HOSPITALS
Donnatal ElixirAyerst Laboratories
Donnatal ExtentabsPBM Pharmaceuticals, Inc
Donnatal Extentabs SrtWyeth Ayerst Canada Inc.
Donnatal TabWyeth Ayerst Canada Inc.
Me-PB-hyosMethod Pharmaceuticals, Llc
Phenaphen No 2 CapAyerst Laboratories
Phenaphen No 3 CapAyerst Laboratories
Phenaphen No 4 CapAyerst Laboratories
Phenaphen No.2 CapWyeth Ayerst Canada Inc.
Phenaphen No.3 CapWyeth Ayerst Canada Inc.
Phenaphen No.4 CapWyeth Ayerst Canada Inc.
PhenohytroWinder Laboratories, LLC
QuadrapaxRebel Distributors Corp
Re-PB Hyos ElixirKAISER FOUNDATION HOSPITALS
Se-donna Pb HyosSeton Pharmaceuticals
Tedral TabParke Davis Division, Warner Lambert Canada Inc.
Salts
Name/CASStructureProperties
Phenobarbital sodium
ThumbNot applicableDBSALT001491
Categories
UNIIYQE403BP4D
CAS number50-06-6
WeightAverage: 232.2353
Monoisotopic: 232.08479226
Chemical FormulaC12H12N2O3
InChI KeyInChIKey=DDBREPKUVSBGFI-UHFFFAOYSA-N
InChI
InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)
IUPAC Name
5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione
SMILES
CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • Benzenoid
  • 1,3-diazinane
  • Monocyclic benzene moiety
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of all types of seizures except absence seizures.
PharmacodynamicsPhenobarbital, the longest-acting barbiturate, is used for its anticonvulsant and sedative-hypnotic properties in the management of all seizure disorders except absence (petit mal).
Mechanism of actionPhenobarbital acts on GABAA receptors, increasing synaptic inhibition. This has the effect of elevating seizure threshold and reducing the spread of seizure activity from a seizure focus. Phenobarbital may also inhibit calcium channels, resulting in a decrease in excitatory transmitter release. The sedative-hypnotic effects of phenobarbital are likely the result of its effect on the polysynaptic midbrain reticular formation, which controls CNS arousal.
Related Articles
AbsorptionAbsorbed in varying degrees following oral, rectal or parenteral administration. The salts are more rapidly absorbed than are the acids. The rate of absorption is increased if the sodium salt is ingested as a dilute solution or taken on an empty stomach.
Volume of distributionNot Available
Protein binding20 to 45%
Metabolism

Hepatic (mostly via CYP2C19).

SubstrateEnzymesProduct
Phenobarbital
p-HydroxyphenobarbitalDetails
p-Hydroxyphenobarbital
Not Available
Phenobarbital O-sulfateDetails
p-Hydroxyphenobarbital
Not Available
Phenobarbital O-glucuronideDetails
Route of eliminationNot Available
Half life53 to 118 hours (mean 79 hours)
ClearanceNot Available
ToxicityCNS and respiratory depression which may progress to Cheyne-Stokes respiration, areflexia, constriction of the pupils to a slight degree (though in severe poisoning they may wshow paralytic dilation), oliguria, tachycardia, hypotension, lowered body temperature, and coma. Typical shock syndrome (apnea, circulatory collapse, respiratory arrest, and death) may occur.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9935
Blood Brain Barrier+0.9736
Caco-2 permeable-0.5561
P-glycoprotein substrateSubstrate0.5157
P-glycoprotein inhibitor INon-inhibitor0.6472
P-glycoprotein inhibitor IINon-inhibitor0.9869
Renal organic cation transporterNon-inhibitor0.9235
CYP450 2C9 substrateNon-substrate0.6962
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7702
CYP450 1A2 substrateNon-inhibitor0.84
CYP450 2C9 inhibitorNon-inhibitor0.9023
CYP450 2D6 inhibitorNon-inhibitor0.9593
CYP450 2C19 inhibitorNon-inhibitor0.8664
CYP450 3A4 inhibitorNon-inhibitor0.9236
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9164
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7469
BiodegradationNot ready biodegradable0.9894
Rat acute toxicity3.1244 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.99
hERG inhibition (predictor II)Non-inhibitor0.9354
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Elixiroral4 mg
Tabletoral
Tablet (extended-release)oral
Tablet, film coated, extended releaseoral
Capsuleoral
Tabletoral100 mg
Tabletoral15 mg
Tabletoral30 mg
Tabletoral60 mg
Elixiroral5 mg
Elixiroral20 mg/5mL
Liquidoral20 mg/5mL
Tabletoral100 mg/1
Tabletoral15 mg/1
Tabletoral16.2 mg/1
Tabletoral30 mg/1
Tabletoral32.4 mg/1
Tabletoral60 mg/1
Tabletoral64.8 mg/1
Tabletoral97.2 mg/1
Injectionintramuscular; intravenous130 mg/mL
Injectionintramuscular; intravenous65 mg/mL
Solutionintramuscular; intravenous; subcutaneous30 mg
Solutionintramuscular; intravenous120 mg
Solutionintramuscular; intravenous30 mg
Elixiroral
Prices
Unit descriptionCostUnit
Phenobarbital 130 mg/ml vial4.32USD ml
Phenobarbital 65 mg/ml vial1.63USD ml
Phenobarbital sodium powder0.36USD g
Pms-Phenobarbital 100 mg Tablet0.15USD tablet
Phenobarbital powder0.13USD g
Pms-Phenobarbital 60 mg Tablet0.11USD tablet
Phenobarbital 97.2 mg tablet0.1USD tablet
Phenobarbital 64.8 mg tablet0.09USD tablet
Pms-Phenobarbital 5 mg/ml Elixir0.09USD ml
Phenobarbital 16.2 mg tablet0.08USD tablet
Phenobarbital 30 mg tablet0.08USD tablet
Phenobarbital 32.4 mg tablet0.08USD tablet
Pms-Phenobarbital 30 mg Tablet0.08USD tablet
Phenobarbital 100 mg tablet0.07USD tablet
Pms-Phenobarbital 15 mg Tablet0.07USD tablet
PHENobarbital 20 mg/5ml Elixir0.06USD ml
Phenobarbital 60 mg tablet0.03USD tablet
Phenobarbital 15 mg tablet0.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point174 °CPhysProp
water solubility1110 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.47HANSCH,C ET AL. (1995)
pKa7.3BUDAVARI,S ET AL. (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.276 mg/mLALOGPS
logP1.4ALOGPS
logP1.41ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)8.14ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity59.75 m3·mol-1ChemAxon
Polarizability22.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.44 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0uxr-6950000000-193bf296d3e5d1705628View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

Tong Sun, Shawn Watson, Rajesh Manchanda, “PHENOBARBITAL SALTS; METHODS OF MAKING; AND METHODS OF USE THEREOF.” U.S. Patent US20100035904, issued February 11, 2010.

US20100035904
General References
  1. Kwan P, Brodie MJ: Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia. 2004 Sep;45(9):1141-9. [PubMed:15329080 ]
  2. Taylor S, Tudur Smith C, Williamson PR, Marson AG: Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev. 2001;(4):CD002217. [PubMed:11687150 ]
  3. Tudur Smith C, Marson AG, Williamson PR: Carbamazepine versus phenobarbitone monotherapy for epilepsy. Cochrane Database Syst Rev. 2003;(1):CD001904. [PubMed:12535420 ]
  4. Kalviainen R, Eriksson K, Parviainen I: Refractory generalised convulsive status epilepticus : a guide to treatment. CNS Drugs. 2005;19(9):759-68. [PubMed:16142991 ]
  5. Booth D, Evans DJ: Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004218. [PubMed:15495087 ]
External Links
ATC CodesN03AA02
AHFS Codes
  • 28:24.04
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (53 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with 3,4-Methylenedioxymethamphetamine.
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be decreased when it is combined with Phenobarbital.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Phenobarbital is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Phenobarbital.
AbirateroneThe metabolism of Phenobarbital can be decreased when combined with Abiraterone.
AcebutololPhenobarbital may increase the hypotensive activities of Acebutolol.
AceclofenacThe metabolism of Aceclofenac can be increased when combined with Phenobarbital.
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Phenobarbital.
AcepromazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Phenobarbital.
AcetaminophenThe serum concentration of Phenobarbital can be increased when it is combined with Acetaminophen.
AcetazolamidePhenobarbital may increase the hypotensive activities of Acetazolamide.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Phenobarbital.
AdinazolamThe metabolism of Adinazolam can be increased when combined with Phenobarbital.
adipiplonThe risk or severity of adverse effects can be increased when Phenobarbital is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Phenobarbital.
AfatinibThe serum concentration of Phenobarbital can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Agomelatine.
AlbendazoleThe serum concentration of the active metabolites of Albendazole can be reduced when Albendazole is used in combination with Phenobarbital resulting in a loss in efficacy.
AlbendazoleThe serum concentration of Phenobarbital can be increased when it is combined with Albendazole.
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Phenobarbital.
AldesleukinPhenobarbital may increase the hypotensive activities of Aldesleukin.
AldosteroneThe serum concentration of Phenobarbital can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Phenobarbital can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Alfaxalone.
AlfentanilThe serum concentration of Phenobarbital can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Alfentanil.
AlfuzosinThe metabolism of Alfuzosin can be increased when combined with Phenobarbital.
AliskirenPhenobarbital may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Phenobarbital.
AllylestrenolThe metabolism of Allylestrenol can be increased when combined with Phenobarbital.
AlmotriptanThe metabolism of Almotriptan can be increased when combined with Phenobarbital.
AlogliptinThe metabolism of Alogliptin can be increased when combined with Phenobarbital.
AlosetronThe metabolism of Alosetron can be increased when combined with Phenobarbital.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Phenobarbital.
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Phenobarbital.
AmantadineThe serum concentration of Phenobarbital can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Phenobarbital.
AmbroxolThe metabolism of Ambroxol can be increased when combined with Phenobarbital.
AmcinonideThe serum concentration of Amcinonide can be decreased when it is combined with Phenobarbital.
AmiloridePhenobarbital may increase the hypotensive activities of Amiloride.
AmineptineThe metabolism of Amineptine can be increased when combined with Phenobarbital.
Aminohippuric acidThe serum concentration of Phenobarbital can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be increased when combined with Phenobarbital.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Phenobarbital.
AmiodaroneThe metabolism of Amiodarone can be increased when combined with Phenobarbital.
AmiodaroneThe serum concentration of Phenobarbital can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Phenobarbital.
AmitriptylineThe serum concentration of Phenobarbital can be increased when it is combined with Amitriptyline.
AmlodipinePhenobarbital may increase the hypotensive activities of Amlodipine.
AmlodipineThe serum concentration of Phenobarbital can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amobarbital.
AmodiaquineThe metabolism of Amodiaquine can be increased when combined with Phenobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amperozide.
AmphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with Amphetamine.
AmprenavirThe metabolism of Amprenavir can be increased when combined with Phenobarbital.
AmprenavirThe serum concentration of Phenobarbital can be decreased when it is combined with Amprenavir.
AmrinoneThe metabolism of Amrinone can be increased when combined with Phenobarbital.
AmsacrineThe serum concentration of Phenobarbital can be increased when it is combined with Amsacrine.
Amyl NitritePhenobarbital may increase the hypotensive activities of Amyl Nitrite.
AnagrelideThe metabolism of Anagrelide can be increased when combined with Phenobarbital.
AntipyrineThe metabolism of Antipyrine can be increased when combined with Phenobarbital.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Phenobarbital.
ApraclonidinePhenobarbital may increase the hypotensive activities of Apraclonidine.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Phenobarbital.
AprepitantThe metabolism of Aprepitant can be increased when combined with Phenobarbital.
Arachidonic AcidThe metabolism of Arachidonic Acid can be increased when combined with Phenobarbital.
ArformoterolThe metabolism of Arformoterol can be increased when combined with Phenobarbital.
ArgatrobanThe metabolism of Argatroban can be increased when combined with Phenobarbital.
AripiprazoleThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Aripiprazole.
ArmodafinilThe metabolism of Phenobarbital can be decreased when combined with Armodafinil.
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Phenobarbital.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Phenobarbital.
ArtemetherThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Phenobarbital resulting in a loss in efficacy.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Phenobarbital resulting in a loss in efficacy.
ArticaineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Articaine.
ASA404The metabolism of ASA404 can be increased when combined with Phenobarbital.
AsenapineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Asenapine.
AstemizoleThe metabolism of Astemizole can be increased when combined with Phenobarbital.
AstemizoleThe serum concentration of Phenobarbital can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Phenobarbital.
AtazanavirThe serum concentration of Phenobarbital can be increased when it is combined with Atazanavir.
AtenololPhenobarbital may increase the hypotensive activities of Atenolol.
AtenololThe serum concentration of Phenobarbital can be increased when it is combined with Atenolol.
AtorvastatinThe metabolism of Atorvastatin can be increased when combined with Phenobarbital.
AtorvastatinThe serum concentration of Phenobarbital can be increased when it is combined with Atorvastatin.
AV650The metabolism of AV650 can be increased when combined with Phenobarbital.
AvanafilThe metabolism of Avanafil can be increased when combined with Phenobarbital.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Phenobarbital.
AzaperoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Azaperone.
AzelastinePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Phenobarbital can be increased when it is combined with Azelastine.
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Phenobarbital.
Azilsartan medoxomilPhenobarbital may increase the hypotensive activities of Azilsartan medoxomil.
AzimilideThe metabolism of Azimilide can be increased when combined with Phenobarbital.
AzithromycinThe metabolism of Azithromycin can be increased when combined with Phenobarbital.
AzithromycinThe serum concentration of Phenobarbital can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Baclofen.
BanoxantroneThe metabolism of Banoxantrone can be increased when combined with Phenobarbital.
BarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Barbital.
BarnidipineThe metabolism of Barnidipine can be increased when combined with Phenobarbital.
BazedoxifeneThe serum concentration of Bazedoxifene can be decreased when it is combined with Phenobarbital.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Phenobarbital.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Phenobarbital.
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Phenobarbital.
BenazeprilPhenobarbital may increase the hypotensive activities of Benazepril.
BendamustineThe serum concentration of Bendamustine can be decreased when it is combined with Phenobarbital.
BendroflumethiazidePhenobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
BenidipineThe metabolism of Benidipine can be increased when combined with Phenobarbital.
BenzocaineThe serum concentration of Phenobarbital can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Benzocaine.
BenzphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with Benzphetamine.
BenzphetamineThe metabolism of Benzphetamine can be increased when combined with Phenobarbital.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Benzyl alcohol.
BepridilThe metabolism of Bepridil can be increased when combined with Phenobarbital.
BepridilThe serum concentration of Phenobarbital can be increased when it is combined with Bepridil.
BeraprostThe metabolism of Beraprost can be increased when combined with Phenobarbital.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Phenobarbital.
BetaxololPhenobarbital may increase the hypotensive activities of Betaxolol.
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Phenobarbital.
BexaroteneThe metabolism of Bexarotene can be increased when combined with Phenobarbital.
BezafibrateThe metabolism of Bezafibrate can be increased when combined with Phenobarbital.
BicalutamideThe metabolism of Bicalutamide can be increased when combined with Phenobarbital.
BiperidenThe serum concentration of Phenobarbital can be increased when it is combined with Biperiden.
BisoprololPhenobarbital may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Phenobarbital.
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Phenobarbital.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Phenobarbital.
BortezomibThe metabolism of Phenobarbital can be decreased when combined with Bortezomib.
BosentanThe metabolism of Bosentan can be increased when combined with Phenobarbital.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Phenobarbital.
BosutinibThe serum concentration of Phenobarbital can be increased when it is combined with Bosutinib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Phenobarbital.
BretyliumPhenobarbital may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
BrimonidinePhenobarbital may increase the hypotensive activities of Brimonidine.
BrinzolamideThe metabolism of Brinzolamide can be increased when combined with Phenobarbital.
BromazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Bromazepam.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Phenobarbital.
BromocriptineThe serum concentration of Phenobarbital can be increased when it is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Brotizolam.
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Phenobarbital.
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Phenobarbital.
BumetanidePhenobarbital may increase the hypotensive activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenobarbital.
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Phenobarbital.
BuprenorphineThe serum concentration of Phenobarbital can be increased when it is combined with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be increased when combined with Phenobarbital.
BuspironeThe serum concentration of Phenobarbital can be increased when it is combined with Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Buspirone.
BusulfanThe metabolism of Busulfan can be increased when combined with Phenobarbital.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Phenobarbital.
ButacaineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenobarbital.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Phenobarbital.
CabazitaxelThe serum concentration of Phenobarbital can be increased when it is combined with Cabazitaxel.
CabergolineThe metabolism of Cabergoline can be increased when combined with Phenobarbital.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Phenobarbital.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Phenobarbital.
CaffeineThe serum concentration of Phenobarbital can be increased when it is combined with Caffeine.
CalcitriolThe metabolism of Calcitriol can be increased when combined with Phenobarbital.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Phenobarbital.
CanagliflozinPhenobarbital may increase the hypotensive activities of Canagliflozin.
CanagliflozinThe serum concentration of Phenobarbital can be increased when it is combined with Canagliflozin.
CandesartanPhenobarbital may increase the hypotensive activities of Candesartan.
CandesartanThe serum concentration of Phenobarbital can be increased when it is combined with Candesartan.
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Phenobarbital.
CapecitabineThe metabolism of Phenobarbital can be decreased when combined with Capecitabine.
CaptoprilPhenobarbital may increase the hypotensive activities of Captopril.
CaptoprilThe serum concentration of Phenobarbital can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Phenobarbital can be decreased when it is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Phenobarbital.
CariprazineThe metabolism of Cariprazine can be increased when combined with Phenobarbital.
CarisoprodolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Carisoprodol.
CarmustineThe metabolism of Carmustine can be increased when combined with Phenobarbital.
CarteololPhenobarbital may increase the hypotensive activities of Carteolol.
CarvedilolPhenobarbital may increase the hypotensive activities of Carvedilol.
CarvedilolThe serum concentration of Phenobarbital can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Phenobarbital can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Celecoxib can be increased when combined with Phenobarbital.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Phenobarbital.
CephalexinThe metabolism of Cephalexin can be increased when combined with Phenobarbital.
CeritinibThe serum concentration of Phenobarbital can be increased when it is combined with Ceritinib.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Phenobarbital.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Phenobarbital.
CetirizineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be increased when combined with Phenobarbital.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be increased when combined with Phenobarbital.
Chloral hydrateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Phenobarbital can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Phenobarbital.
ChlormezanoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Phenobarbital.
ChloroquineThe metabolism of Chloroquine can be increased when combined with Phenobarbital.
ChloroquineThe serum concentration of Phenobarbital can be increased when it is combined with Chloroquine.
ChlorothiazidePhenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chlorphenamine.
ChlorphentermineThe serum concentration of Phenobarbital can be decreased when it is combined with Chlorphentermine.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Phenobarbital.
ChlorpromazineThe serum concentration of Phenobarbital can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Phenobarbital can be increased when it is combined with Chlorpropamide.
ChlorpropamideThe metabolism of Chlorpropamide can be increased when combined with Phenobarbital.
ChlorprothixeneThe serum concentration of Phenobarbital can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chlorprothixene.
ChlorthalidonePhenobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Cholecalciferol can be increased when combined with Phenobarbital.
CholesterolThe serum concentration of Phenobarbital can be increased when it is combined with Cholesterol.
CholestyramineThe serum concentration of Phenobarbital can be decreased when it is combined with Cholestyramine.
Cholic AcidThe serum concentration of Phenobarbital can be decreased when it is combined with Cholic Acid.
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Phenobarbital.
CilazaprilPhenobarbital may increase the hypotensive activities of Cilazapril.
CilazaprilThe serum concentration of Phenobarbital can be increased when it is combined with Cilazapril.
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Phenobarbital.
CilostazolThe metabolism of Cilostazol can be increased when combined with Phenobarbital.
CimetidineThe serum concentration of Phenobarbital can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Cinacalcet can be increased when combined with Phenobarbital.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Phenobarbital.
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Phenobarbital.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Phenobarbital.
CiprofloxacinThe serum concentration of Phenobarbital can be increased when it is combined with Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be increased when combined with Phenobarbital.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Phenobarbital.
CitalopramThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Citalopram.
CitalopramThe serum concentration of Phenobarbital can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Phenobarbital.
ClarithromycinThe serum concentration of Phenobarbital can be increased when it is combined with Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Clemastine.
ClenbuterolThe metabolism of Clenbuterol can be increased when combined with Phenobarbital.
ClevidipinePhenobarbital may increase the hypotensive activities of Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Clidinium.
ClindamycinThe metabolism of Clindamycin can be increased when combined with Phenobarbital.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Phenobarbital.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Phenobarbital.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be decreased when it is combined with Phenobarbital.
ClocortoloneThe serum concentration of Clocortolone can be decreased when it is combined with Phenobarbital.
ClofazimineThe metabolism of Clofazimine can be increased when combined with Phenobarbital.
ClofazimineThe serum concentration of Phenobarbital can be increased when it is combined with Clofazimine.
ClofibrateThe metabolism of Clofibrate can be increased when combined with Phenobarbital.
clomethiazoleThe risk or severity of adverse effects can be increased when Phenobarbital is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Phenobarbital.
ClomipramineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Clomipramine.
ClomipramineThe serum concentration of Phenobarbital can be increased when it is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Clonazepam.
ClonidinePhenobarbital may increase the hypotensive activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Phenobarbital.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Phenobarbital.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Phenobarbital.
ClotiazepamThe metabolism of Clotiazepam can be increased when combined with Phenobarbital.
ClotrimazoleThe serum concentration of Phenobarbital can be decreased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Phenobarbital.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Phenobarbital.
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Phenobarbital.
CobicistatThe serum concentration of Phenobarbital can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Phenobarbital.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Phenobarbital.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Phenobarbital.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Phenobarbital.
ColchicineThe serum concentration of Phenobarbital can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Phenobarbital can be increased when it is combined with Colforsin.
ConivaptanThe metabolism of Conivaptan can be increased when combined with Phenobarbital.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Phenobarbital.
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Phenobarbital.
CosyntropinCosyntropin may increase the hepatotoxic activities of Phenobarbital.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Phenobarbital.
CrizotinibThe serum concentration of Phenobarbital can be increased when it is combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenobarbital.
CyclophosphamideThe metabolism of Cyclophosphamide can be increased when combined with Phenobarbital.
CyclophosphamideThe serum concentration of Phenobarbital can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Phenobarbital can be decreased when it is combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Phenobarbital can be decreased when it is combined with Cyproterone acetate.
CytarabineThe metabolism of Cytarabine can be increased when combined with Phenobarbital.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Phenobarbital.
DabrafenibThe serum concentration of Phenobarbital can be decreased when it is combined with Dabrafenib.
DacarbazineThe metabolism of Dacarbazine can be increased when combined with Phenobarbital.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Phenobarbital.
DaclatasvirThe serum concentration of Phenobarbital can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Phenobarbital.
DactinomycinThe serum concentration of Phenobarbital can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dantrolene.
DapagliflozinPhenobarbital may increase the hypotensive activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenobarbital.
DapoxetineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dapoxetine.
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Phenobarbital.
DapsoneThe metabolism of Dapsone can be increased when combined with Phenobarbital.
DarifenacinThe metabolism of Darifenacin can be increased when combined with Phenobarbital.
DarodipineThe metabolism of Darodipine can be increased when combined with Phenobarbital.
DarunavirThe serum concentration of Phenobarbital can be decreased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be increased when combined with Phenobarbital.
DasabuvirThe metabolism of Dasabuvir can be increased when combined with Phenobarbital.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Phenobarbital.
DasatinibThe serum concentration of Phenobarbital can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Phenobarbital.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Phenobarbital.
DeferasiroxThe serum concentration of Deferasirox can be decreased when it is combined with Phenobarbital.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be decreased when it is combined with Phenobarbital.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Phenobarbital.
DelavirdineThe metabolism of Delavirdine can be increased when combined with Phenobarbital.
deramciclaneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Desflurane.
DesipramineThe serum concentration of Phenobarbital can be increased when it is combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Desipramine.
DesloratadineThe serum concentration of Phenobarbital can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Desloratadine.
DesoximetasoneThe serum concentration of Desoximetasone can be decreased when it is combined with Phenobarbital.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Phenobarbital.
DesvenlafaxineThe metabolism of Desvenlafaxine can be increased when combined with Phenobarbital.
DetomidineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Detomidine.
DexamethasoneThe serum concentration of Phenobarbital can be decreased when it is combined with Dexamethasone.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Phenobarbital.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dexbrompheniramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be increased when combined with Phenobarbital.
DexmedetomidinePhenobarbital may increase the hypotensive activities of Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Phenobarbital.
DexmethylphenidateThe serum concentration of Phenobarbital can be increased when it is combined with Dexmethylphenidate.
DextroamphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with Dextroamphetamine.
DextromethorphanThe metabolism of Dextromethorphan can be increased when combined with Phenobarbital.
DextromethorphanThe serum concentration of Phenobarbital can be increased when it is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Phenobarbital.
DezocineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Phenobarbital.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Phenobarbital.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Phenobarbital.
DiclofenacThe serum concentration of Phenobarbital can be increased when it is combined with Diclofenac.
DiclofenamidePhenobarbital may increase the hypotensive activities of Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Phenobarbital.
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Phenobarbital.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Phenobarbital.
DifenoxinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Difenoxin.
DiflorasoneThe serum concentration of Diflorasone can be decreased when it is combined with Phenobarbital.
DifluocortoloneThe serum concentration of Difluocortolone can be decreased when it is combined with Phenobarbital.
DifluprednateThe serum concentration of Difluprednate can be decreased when it is combined with Phenobarbital.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Phenobarbital.
DigoxinThe serum concentration of Phenobarbital can be decreased when it is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Dihydroergotamine can be increased when combined with Phenobarbital.
DihydroergotamineThe serum concentration of Phenobarbital can be increased when it is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Phenobarbital.
DiltiazemPhenobarbital may increase the hypotensive activities of Diltiazem.
DiltiazemThe serum concentration of Phenobarbital can be increased when it is combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dimenhydrinate.
DinoprostoneThe metabolism of Dinoprostone can be increased when combined with Phenobarbital.
DinutuximabPhenobarbital may increase the hypotensive activities of Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenobarbital.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenobarbital.
DipyridamolePhenobarbital may increase the hypotensive activities of Dipyridamole.
DipyridamoleThe serum concentration of Phenobarbital can be increased when it is combined with Dipyridamole.
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Phenobarbital.
DisulfiramThe metabolism of Disulfiram can be increased when combined with Phenobarbital.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Phenobarbital.
DofetilideThe metabolism of Dofetilide can be increased when combined with Phenobarbital.
DolasetronThe metabolism of Dolasetron can be increased when combined with Phenobarbital.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Phenobarbital.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Phenobarbital.
DonepezilThe metabolism of Donepezil can be increased when combined with Phenobarbital.
DopamineThe metabolism of Dopamine can be increased when combined with Phenobarbital.
DoramectinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Doramectin.
DorzolamideThe metabolism of Dorzolamide can be increased when combined with Phenobarbital.
DosulepinThe metabolism of Dosulepin can be increased when combined with Phenobarbital.
DotarizineThe metabolism of Dotarizine can be increased when combined with Phenobarbital.
DoxazosinPhenobarbital may increase the hypotensive activities of Doxazosin.
DoxazosinThe serum concentration of Phenobarbital can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Phenobarbital can be increased when it is combined with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Phenobarbital.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Phenobarbital.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
DoxylamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Phenobarbital is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Phenobarbital.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Phenobarbital.
DronedaroneThe serum concentration of Phenobarbital can be increased when it is combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Phenobarbital.
DrotebanolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Drotebanol.
DuloxetineThe metabolism of Duloxetine can be increased when combined with Phenobarbital.
DutasterideThe metabolism of Dutasteride can be increased when combined with Phenobarbital.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Phenobarbital.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Phenobarbital.
EcgonineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Phenobarbital is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Phenobarbital.
EfavirenzThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Efavirenz.
EfonidipineThe metabolism of Efonidipine can be increased when combined with Phenobarbital.
ElbasvirThe serum concentration of Phenobarbital can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Phenobarbital.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Phenobarbital.
EltrombopagThe metabolism of Eltrombopag can be increased when combined with Phenobarbital.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Phenobarbital.
EmpagliflozinPhenobarbital may increase the hypotensive activities of Empagliflozin.
EnalaprilPhenobarbital may increase the hypotensive activities of Enalapril.
EnalaprilThe serum concentration of Phenobarbital can be increased when it is combined with Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Phenobarbital.
EntacaponeThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Entacapone.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Phenobarbital.
EnzalutamideThe serum concentration of Phenobarbital can be increased when it is combined with Enzalutamide.
EperisoneThe metabolism of Eperisone can be increased when combined with Phenobarbital.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Phenobarbital.
EplerenonePhenobarbital may increase the hypotensive activities of Eplerenone.
EpoprostenolThe metabolism of Epoprostenol can be increased when combined with Phenobarbital.
EprosartanPhenobarbital may increase the hypotensive activities of Eprosartan.
EquileninThe serum concentration of Equilenin can be decreased when it is combined with Phenobarbital.
EquilinThe serum concentration of Equilin can be decreased when it is combined with Phenobarbital.
ErgocalciferolThe metabolism of Ergocalciferol can be increased when combined with Phenobarbital.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be increased when combined with Phenobarbital.
ErgonovineThe metabolism of Ergonovine can be increased when combined with Phenobarbital.
ErgonovineThe serum concentration of Phenobarbital can be increased when it is combined with Ergonovine.
ErgotamineThe metabolism of Ergotamine can be increased when combined with Phenobarbital.
ErgotamineThe serum concentration of Phenobarbital can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Phenobarbital.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Phenobarbital.
EscitalopramThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Phenobarbital.
Eslicarbazepine acetateThe metabolism of Phenobarbital can be decreased when combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Phenobarbital.
EsmololPhenobarbital may increase the hypotensive activities of Esmolol.
EsomeprazoleThe metabolism of Esomeprazole can be increased when combined with Phenobarbital.
EstazolamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Phenobarbital.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be increased when combined with Phenobarbital.
EstramustineThe metabolism of Estramustine can be increased when combined with Phenobarbital.
EstramustineThe serum concentration of Phenobarbital can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Phenobarbital.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Phenobarbital.
Estrone sulfateThe metabolism of Estrone sulfate can be increased when combined with Phenobarbital.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Phenobarbital.
Etacrynic acidPhenobarbital may increase the hypotensive activities of Etacrynic acid.
EthanolPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Phenobarbital.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Phenobarbital.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Phenobarbital.
EthosuximideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethotoin.
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Phenobarbital.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etizolam.
EtodolacThe metabolism of Etodolac can be increased when combined with Phenobarbital.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenobarbital.
EtonogestrelThe metabolism of Etonogestrel can be increased when combined with Phenobarbital.
EtoperidoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Phenobarbital.
EtoposideThe serum concentration of Phenobarbital can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be increased when combined with Phenobarbital.
EtorphineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etorphine.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Phenobarbital.
EtravirineThe serum concentration of Phenobarbital can be increased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Phenobarbital.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Phenobarbital.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Phenobarbital.
EzogabineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ezogabine.
FamciclovirThe metabolism of Famciclovir can be increased when combined with Phenobarbital.
FelbamateThe serum concentration of Phenobarbital can be increased when it is combined with Felbamate.
FelbamateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Felbamate.
FelodipinePhenobarbital may increase the hypotensive activities of Felodipine.
FelodipineThe serum concentration of Phenobarbital can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fencamfamine.
FendilineThe metabolism of Fendiline can be increased when combined with Phenobarbital.
FenfluramineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fenfluramine.
FenofibrateThe metabolism of Fenofibrate can be increased when combined with Phenobarbital.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Phenobarbital.
FentanylThe serum concentration of Phenobarbital can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Phenobarbital.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Phenobarbital.
FexofenadineThe serum concentration of Phenobarbital can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Phenobarbital.
FidaxomicinThe serum concentration of Phenobarbital can be increased when it is combined with Fidaxomicin.
FinasterideThe metabolism of Finasteride can be increased when combined with Phenobarbital.
FingolimodThe metabolism of Fingolimod can be increased when combined with Phenobarbital.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Phenobarbital.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Phenobarbital.
FloxuridineThe metabolism of Phenobarbital can be decreased when combined with Floxuridine.
FluconazoleThe serum concentration of Phenobarbital can be increased when it is combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fludiazepam.
FludrocortisoneThe serum concentration of Fludrocortisone can be decreased when it is combined with Phenobarbital.
FlumethasoneThe serum concentration of Flumethasone can be decreased when it is combined with Phenobarbital.
FlunarizineThe metabolism of Flunarizine can be increased when combined with Phenobarbital.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Phenobarbital.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Phenobarbital.
FlunitrazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Flunitrazepam.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Phenobarbital.
FluocinonideThe serum concentration of Fluocinonide can be decreased when it is combined with Phenobarbital.
FluocortoloneThe serum concentration of Fluocortolone can be decreased when it is combined with Phenobarbital.
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Phenobarbital.
FluorouracilThe metabolism of Fluorouracil can be increased when combined with Phenobarbital.
FluoxetineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluoxetine.
FluoxetineThe serum concentration of Phenobarbital can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Phenobarbital can be increased when it is combined with Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Flupentixol.
FluphenazineThe serum concentration of Phenobarbital can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluphenazine.
FluprednideneThe serum concentration of Fluprednidene can be decreased when it is combined with Phenobarbital.
FluprednisoloneThe serum concentration of Fluprednisolone can be decreased when it is combined with Phenobarbital.
FlurandrenolideThe serum concentration of Flurandrenolide can be decreased when it is combined with Phenobarbital.
FlurazepamThe serum concentration of Phenobarbital can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Flurazepam.
FlurbiprofenThe metabolism of Flurbiprofen can be increased when combined with Phenobarbital.
FluspirileneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluspirilene.
FlutamideThe metabolism of Flutamide can be increased when combined with Phenobarbital.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Phenobarbital.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Fluvastatin can be increased when combined with Phenobarbital.
FluvoxamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluvoxamine.
FluvoxamineThe serum concentration of Phenobarbital can be increased when it is combined with Fluvoxamine.
Folic AcidThe serum concentration of Phenobarbital can be decreased when it is combined with Folic Acid.
FormoterolThe metabolism of Formoterol can be increased when combined with Phenobarbital.
FosamprenavirThe metabolism of Fosamprenavir can be increased when combined with Phenobarbital.
FosinoprilPhenobarbital may increase the hypotensive activities of Fosinopril.
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
FosphenytoinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fospropofol.
FrovatriptanThe metabolism of Frovatriptan can be increased when combined with Phenobarbital.
FulvestrantThe metabolism of Fulvestrant can be increased when combined with Phenobarbital.
FurosemidePhenobarbital may increase the hypotensive activities of Furosemide.
GabapentinThe metabolism of Gabapentin can be increased when combined with Phenobarbital.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Phenobarbital.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Phenobarbital is combined with gabapentin enacarbil.
GalantamineThe metabolism of Galantamine can be increased when combined with Phenobarbital.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Gamma Hydroxybutyric Acid.
GavestinelThe metabolism of Gavestinel can be increased when combined with Phenobarbital.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Phenobarbital.
GefitinibThe serum concentration of Phenobarbital can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Phenobarbital.
GemfibrozilThe metabolism of Gemfibrozil can be increased when combined with Phenobarbital.
GenisteinThe serum concentration of Phenobarbital can be increased when it is combined with Genistein.
GenisteinThe metabolism of Genistein can be increased when combined with Phenobarbital.
GliclazideThe metabolism of Gliclazide can be increased when combined with Phenobarbital.
GlimepirideThe metabolism of Glimepiride can be increased when combined with Phenobarbital.
GlipizideThe metabolism of Glipizide can be increased when combined with Phenobarbital.
GlutethimideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Glutethimide.
GlyburideThe metabolism of Glyburide can be increased when combined with Phenobarbital.
GlyburideThe serum concentration of Phenobarbital can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Phenobarbital can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Phenobarbital can be increased when it is combined with Gramicidin D.
GranisetronThe metabolism of Granisetron can be increased when combined with Phenobarbital.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Phenobarbital.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Phenobarbital.
GrepafloxacinThe serum concentration of Phenobarbital can be increased when it is combined with Grepafloxacin.
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Phenobarbital.
GuanabenzThe metabolism of Guanabenz can be increased when combined with Phenobarbital.
GuanfacinePhenobarbital may increase the hypotensive activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Phenobarbital.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Phenobarbital.
HalofantrineThe metabolism of Halofantrine can be increased when combined with Phenobarbital.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Phenobarbital.
HaloperidolThe serum concentration of Phenobarbital can be increased when it is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Phenobarbital.
HeroinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Heroin.
HesperetinThe metabolism of Hesperetin can be increased when combined with Phenobarbital.
HexobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Hexobarbital.
Histamine PhosphateThe metabolism of Histamine Phosphate can be increased when combined with Phenobarbital.
HydralazinePhenobarbital may increase the hypotensive activities of Hydralazine.
HydrochlorothiazidePhenobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Phenobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Phenobarbital.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Phenobarbital.
HydrocortisoneThe serum concentration of Phenobarbital can be increased when it is combined with Hydrocortisone.
HydroflumethiazidePhenobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Phenobarbital.
Hydroxyamphetamine hydrobromideThe serum concentration of Phenobarbital can be decreased when it is combined with Hydroxyamphetamine hydrobromide.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be increased when combined with Phenobarbital.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
HydroxyzineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Hydroxyzine.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Phenobarbital.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Phenobarbital.
IdarubicinThe metabolism of Idarubicin can be increased when combined with Phenobarbital.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Phenobarbital.
IdelalisibThe serum concentration of Phenobarbital can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Phenobarbital.
IloperidoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Phenobarbital.
ImatinibThe serum concentration of Phenobarbital can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Phenobarbital.
ImipramineThe serum concentration of Phenobarbital can be increased when it is combined with Imipramine.
ImiquimodThe metabolism of Imiquimod can be increased when combined with Phenobarbital.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Phenobarbital.
IndalpineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Indalpine.
IndapamidePhenobarbital may increase the orthostatic hypotensive activities of Indapamide.
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Phenobarbital.
IndinavirThe serum concentration of Phenobarbital can be decreased when it is combined with Indinavir.
indisulamThe metabolism of indisulam can be increased when combined with Phenobarbital.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Phenobarbital.
IndomethacinThe serum concentration of Phenobarbital can be increased when it is combined with Indomethacin.
Ipratropium bromideThe metabolism of Ipratropium bromide can be increased when combined with Phenobarbital.
IrbesartanPhenobarbital may increase the hypotensive activities of Irbesartan.
IrbesartanThe metabolism of Phenobarbital can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be reduced when Irinotecan is used in combination with Phenobarbital resulting in a loss in efficacy.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Phenobarbital resulting in a loss in efficacy.
IsavuconazoniumThe serum concentration of Phenobarbital can be increased when it is combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Phenobarbital.
IsoniazidThe metabolism of Phenobarbital can be decreased when combined with Isoniazid.
Isosorbide DinitratePhenobarbital may increase the hypotensive activities of Isosorbide Dinitrate.
Isosorbide MononitratePhenobarbital may increase the hypotensive activities of Isosorbide Mononitrate.
IsoxsuprinePhenobarbital may increase the hypotensive activities of Isoxsuprine.
IsradipinePhenobarbital may increase the hypotensive activities of Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Phenobarbital.
ItraconazoleThe serum concentration of Phenobarbital can be increased when it is combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Phenobarbital.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Phenobarbital.
IvacaftorThe serum concentration of Phenobarbital can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Phenobarbital.
IvermectinThe serum concentration of Phenobarbital can be increased when it is combined with Ivermectin.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Phenobarbital.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Phenobarbital.
KetamineThe serum concentration of Phenobarbital can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Phenobarbital.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Phenobarbital.
KetobemidoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Phenobarbital.
KetoconazoleThe serum concentration of Phenobarbital can be increased when it is combined with Ketoconazole.
KetoprofenThe metabolism of Ketoprofen can be increased when combined with Phenobarbital.
LabetalolPhenobarbital may increase the hypotensive activities of Labetalol.
LacidipineThe metabolism of Lacidipine can be increased when combined with Phenobarbital.
LacosamideThe serum concentration of Lacosamide can be decreased when it is combined with Phenobarbital.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Phenobarbital.
LamotrigineThe metabolism of Lamotrigine can be increased when combined with Phenobarbital.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Phenobarbital.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Phenobarbital.
LansoprazoleThe serum concentration of Phenobarbital can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Phenobarbital.
LapatinibThe serum concentration of Phenobarbital can be increased when it is combined with Lapatinib.
LaquinimodThe metabolism of Laquinimod can be increased when combined with Phenobarbital.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Phenobarbital.
LeflunomideThe metabolism of Leflunomide can be increased when combined with Phenobarbital.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Phenobarbital.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Phenobarbital.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Phenobarbital.
LesinuradThe metabolism of Lesinurad can be increased when combined with Phenobarbital.
LetrozoleThe metabolism of Letrozole can be increased when combined with Phenobarbital.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Phenobarbital.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Phenobarbital.
LevobunololPhenobarbital may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Phenobarbital.
LevocabastineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Phenobarbital.
LevofloxacinThe serum concentration of Phenobarbital can be increased when it is combined with Levofloxacin.
LevomefolateThe serum concentration of Phenobarbital can be decreased when it is combined with Levomefolate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Levomilnacipran.
LevonorgestrelThe metabolism of Levonorgestrel can be increased when combined with Phenobarbital.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenobarbital.
LevothyroxineThe metabolism of Levothyroxine can be increased when combined with Phenobarbital.
LevothyroxineThe serum concentration of Phenobarbital can be decreased when it is combined with Levothyroxine.
LicofeloneThe metabolism of Licofelone can be increased when combined with Phenobarbital.
LidocaineThe serum concentration of Phenobarbital can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Phenobarbital.
LiothyronineThe serum concentration of Phenobarbital can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Phenobarbital can be decreased when it is combined with Liotrix.
LisdexamfetamineThe serum concentration of Phenobarbital can be decreased when it is combined with Lisdexamfetamine.
LisinoprilPhenobarbital may increase the hypotensive activities of Lisinopril.
LisinoprilThe serum concentration of Phenobarbital can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be increased when combined with Phenobarbital.
LithiumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lofentanil.
LomefloxacinThe metabolism of Lomefloxacin can be increased when combined with Phenobarbital.
LomitapideThe metabolism of Lomitapide can be increased when combined with Phenobarbital.
LomitapideThe serum concentration of Phenobarbital can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Phenobarbital.
LoperamideThe serum concentration of Phenobarbital can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Phenobarbital.
LopinavirThe serum concentration of Phenobarbital can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Phenobarbital can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Phenobarbital.
LorcaserinThe metabolism of Lorcaserin can be increased when combined with Phenobarbital.
LornoxicamThe metabolism of Lornoxicam can be increased when combined with Phenobarbital.
LosartanPhenobarbital may increase the hypotensive activities of Losartan.
LosartanThe serum concentration of Phenobarbital can be increased when it is combined with Losartan.
LovastatinThe metabolism of Lovastatin can be increased when combined with Phenobarbital.
LovastatinThe serum concentration of Phenobarbital can be increased when it is combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Phenobarbital.
Lu AA21004The risk or severity of adverse effects can be increased when Phenobarbital is combined with Lu AA21004.
LuliconazoleThe serum concentration of Phenobarbital can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Phenobarbital can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Phenobarbital.
LumiracoxibThe metabolism of Lumiracoxib can be increased when combined with Phenobarbital.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Phenobarbital.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Phenobarbital.
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Phenobarbital.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
Magnesium SulfateThe metabolism of Magnesium Sulfate can be increased when combined with Phenobarbital.
MalathionThe metabolism of Malathion can be increased when combined with Phenobarbital.
ManidipineThe metabolism of Manidipine can be increased when combined with Phenobarbital.
MannitolPhenobarbital may increase the hypotensive activities of Mannitol.
MaprotilineThe serum concentration of Phenobarbital can be increased when it is combined with Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Maprotiline.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Phenobarbital.
MebendazoleThe metabolism of Mebendazole can be increased when combined with Phenobarbital.
MebendazoleThe serum concentration of Phenobarbital can be increased when it is combined with Mebendazole.
MecamylaminePhenobarbital may increase the hypotensive activities of Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Medetomidine.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be increased when combined with Phenobarbital.
MedrysoneThe serum concentration of Medrysone can be decreased when it is combined with Phenobarbital.
Mefenamic acidThe metabolism of Mefenamic acid can be increased when combined with Phenobarbital.
MefloquineThe metabolism of Mefloquine can be increased when combined with Phenobarbital.
MefloquineThe serum concentration of Phenobarbital can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Phenobarbital can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Phenobarbital.
MelengestrolThe serum concentration of Melengestrol can be decreased when it is combined with Phenobarbital.
MeloxicamThe metabolism of Meloxicam can be increased when combined with Phenobarbital.
MelperoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Melperone.
MenadioneThe metabolism of Menadione can be increased when combined with Phenobarbital.
MephentermineThe serum concentration of Phenobarbital can be decreased when it is combined with Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be increased when combined with Phenobarbital.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Phenobarbital.
MeprobamateThe serum concentration of Phenobarbital can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Phenobarbital.
MestranolThe metabolism of Mestranol can be increased when combined with Phenobarbital.
MetaxaloneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Metaxalone.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Phenobarbital.
MethadoneThe serum concentration of Phenobarbital can be increased when it is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methadyl Acetate.
MethamphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methaqualone.
MethazolamidePhenobarbital may increase the hypotensive activities of Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Phenobarbital.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Phenobarbital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methotrimeprazine.
MethoxsalenThe metabolism of Methoxsalen can be increased when combined with Phenobarbital.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Phenobarbital.
MethsuximideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methsuximide.
MethyclothiazidePhenobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
MethyldopaPhenobarbital may increase the hypotensive activities of Methyldopa.
MethylphenidateThe serum concentration of Phenobarbital can be increased when it is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Phenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Phenobarbital.
MethyltestosteroneThe metabolism of Methyltestosterone can be increased when combined with Phenobarbital.
MetipranololPhenobarbital may increase the hypotensive activities of Metipranolol.
MetolazonePhenobarbital may increase the orthostatic hypotensive activities of Metolazone.
MetoprololPhenobarbital may increase the hypotensive activities of Metoprolol.
MetoprololThe serum concentration of Phenobarbital can be increased when it is combined with Metoprolol.
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Phenobarbital.
MetyrosinePhenobarbital may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Mexiletine can be increased when combined with Phenobarbital.
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
MianserinThe metabolism of Mianserin can be increased when combined with Phenobarbital.
MibefradilThe metabolism of Mibefradil can be increased when combined with Phenobarbital.
MibefradilThe serum concentration of Phenobarbital can be increased when it is combined with Mibefradil.
MiconazoleThe metabolism of Miconazole can be increased when combined with Phenobarbital.
MiconazoleThe serum concentration of Phenobarbital can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Phenobarbital.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Phenobarbital.
MilnacipranThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
MinoxidilPhenobarbital may increase the hypotensive activities of Minoxidil.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Phenobarbital.
MirtazapinePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Phenobarbital.
MitomycinThe serum concentration of Phenobarbital can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Phenobarbital.
MoclobemideThe metabolism of Phenobarbital can be decreased when combined with Moclobemide.
ModafinilThe metabolism of Modafinil can be increased when combined with Phenobarbital.
MoexiprilPhenobarbital may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Molindone.
MometasoneThe serum concentration of Mometasone can be decreased when it is combined with Phenobarbital.
MontelukastThe metabolism of Montelukast can be increased when combined with Phenobarbital.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Phenobarbital.
MorphineThe serum concentration of Phenobarbital can be increased when it is combined with Morphine.
muraglitazarThe metabolism of muraglitazar can be increased when combined with Phenobarbital.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Phenobarbital.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
NabiloneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nabilone.
NabumetoneThe metabolism of Nabumetone can be increased when combined with Phenobarbital.
NadololPhenobarbital may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenobarbital.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Phenobarbital.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Phenobarbital.
NaltrexoneThe serum concentration of Phenobarbital can be increased when it is combined with Naltrexone.
NaproxenThe metabolism of Naproxen can be increased when combined with Phenobarbital.
NaringeninThe serum concentration of Phenobarbital can be increased when it is combined with Naringenin.
NateglinideThe metabolism of Nateglinide can be increased when combined with Phenobarbital.
NebivololPhenobarbital may increase the hypotensive activities of Nebivolol.
NefazodoneThe metabolism of Nefazodone can be increased when combined with Phenobarbital.
NefazodoneThe serum concentration of Phenobarbital can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Phenobarbital can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Phenobarbital can be increased when it is combined with Neostigmine.
NesiritidePhenobarbital may increase the hypotensive activities of Nesiritide.
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Phenobarbital.
NevirapineThe metabolism of Nevirapine can be increased when combined with Phenobarbital.
NicardipinePhenobarbital may increase the hypotensive activities of Nicardipine.
NicardipineThe serum concentration of Phenobarbital can be increased when it is combined with Nicardipine.
NiclosamideThe metabolism of Niclosamide can be increased when combined with Phenobarbital.
NicotineThe metabolism of Nicotine can be increased when combined with Phenobarbital.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Phenobarbital.
NiguldipineThe metabolism of Niguldipine can be increased when combined with Phenobarbital.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Phenobarbital.
NilotinibThe serum concentration of Phenobarbital can be increased when it is combined with Nilotinib.
NiludipineThe metabolism of Niludipine can be increased when combined with Phenobarbital.
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Phenobarbital.
NimesulideThe metabolism of Nimesulide can be increased when combined with Phenobarbital.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Phenobarbital.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Phenobarbital.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Phenobarbital.
NisoldipineThe serum concentration of Phenobarbital can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Phenobarbital can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Phenobarbital.
NitrendipineThe serum concentration of Phenobarbital can be increased when it is combined with Nitrendipine.
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Phenobarbital.
Nitric OxideThe metabolism of Nitric Oxide can be increased when combined with Phenobarbital.
NitroglycerinPhenobarbital may increase the hypotensive activities of Nitroglycerin.
NitroprussidePhenobarbital may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Phenobarbital.
NorethisteroneThe metabolism of Norethisterone can be increased when combined with Phenobarbital.
NorethisteroneThe serum concentration of Phenobarbital can be decreased when it is combined with Norethisterone.
NorgestrelThe metabolism of Norgestrel can be increased when combined with Phenobarbital.
NormethadoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Olanzapine.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Phenobarbital.
OlmesartanPhenobarbital may increase the hypotensive activities of Olmesartan.
OlodaterolThe metabolism of Olodaterol can be increased when combined with Phenobarbital.
OlopatadineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Phenobarbital.
OmeprazoleThe metabolism of Omeprazole can be increased when combined with Phenobarbital.
OmeprazoleThe serum concentration of Phenobarbital can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Phenobarbital.
OpiumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Opium.
OrlistatThe serum concentration of Phenobarbital can be decreased when it is combined with Orlistat.
OrphenadrinePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Phenobarbital.
OsanetantThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Osanetant.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Phenobarbital.
OspemifeneThe metabolism of Ospemifene can be increased when combined with Phenobarbital.
OxaliplatinThe metabolism of Oxaliplatin can be increased when combined with Phenobarbital.
OxaprozinThe metabolism of Oxaprozin can be increased when combined with Phenobarbital.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Phenobarbital.
OxcarbazepineThe serum concentration of the active metabolites of Oxcarbazepine can be reduced when Oxcarbazepine is used in combination with Phenobarbital resulting in a loss in efficacy.
OxprenololThe serum concentration of Oxprenolol can be decreased when it is combined with Phenobarbital.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Phenobarbital.
OxtriphyllineThe metabolism of Oxtriphylline can be increased when combined with Phenobarbital.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Phenobarbital.
OxybutyninThe metabolism of Oxybutynin can be increased when combined with Phenobarbital.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phenobarbital.
OxymorphoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Oxymorphone.
P-NitrophenolThe serum concentration of Phenobarbital can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Phenobarbital.
PaclitaxelThe serum concentration of Phenobarbital can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Phenobarbital.
PaliperidoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Paliperidone.
Palmitic AcidThe serum concentration of Phenobarbital can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be increased when combined with Phenobarbital.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Phenobarbital.
PantoprazoleThe metabolism of Pantoprazole can be increased when combined with Phenobarbital.
PantoprazoleThe serum concentration of Phenobarbital can be increased when it is combined with Pantoprazole.
PapaverinePhenobarbital may increase the hypotensive activities of Papaverine.
ParaldehydePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Phenobarbital.
ParamethadioneThe metabolism of Paramethadione can be increased when combined with Phenobarbital.
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Phenobarbital.
ParecoxibThe metabolism of Parecoxib can be increased when combined with Phenobarbital.
ParicalcitolThe metabolism of Paricalcitol can be increased when combined with Phenobarbital.
ParitaprevirThe metabolism of Paritaprevir can be increased when combined with Phenobarbital.
ParoxetineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Paroxetine.
ParoxetineThe serum concentration of Phenobarbital can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Phenobarbital.
PenbutololPhenobarbital may increase the hypotensive activities of Penbutolol.
PentamidineThe metabolism of Pentamidine can be increased when combined with Phenobarbital.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Phenobarbital.
PentoxifyllineThe metabolism of Pentoxifylline can be increased when combined with Phenobarbital.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Phenobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Phenobarbital.
PergolideThe metabolism of Pergolide can be increased when combined with Phenobarbital.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Phenobarbital.
PerindoprilPhenobarbital may increase the hypotensive activities of Perindopril.
PerindoprilThe serum concentration of Phenobarbital can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be increased when combined with Phenobarbital.
PerospironeThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Phenobarbital.
PethidinePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Phenobarbital.
PhenacetinThe metabolism of Phenacetin can be increased when combined with Phenobarbital.
PhenindioneThe metabolism of Phenindione can be increased when combined with Phenobarbital.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be increased when combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Phenoxyethanol.
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Phenobarbital.
PhentermineThe serum concentration of Phenobarbital can be decreased when it is combined with Phentermine.
PhenylbutazoneThe metabolism of Phenylbutazone can be increased when combined with Phenobarbital.
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Phenobarbital.
PilocarpineThe metabolism of Pilocarpine can be increased when combined with Phenobarbital.
PimecrolimusThe metabolism of Pimecrolimus can be increased when combined with Phenobarbital.
PimozideThe serum concentration of Phenobarbital can be increased when it is combined with Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pimozide.
PinacidilThe metabolism of Pinacidil can be increased when combined with Phenobarbital.
PinaveriumThe metabolism of Pinaverium can be increased when combined with Phenobarbital.
PindololPhenobarbital may increase the hypotensive activities of Pindolol.
PioglitazoneThe metabolism of Pioglitazone can be increased when combined with Phenobarbital.
PipamperoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pipotiazine.
PirfenidoneThe serum concentration of Pirfenidone can be decreased when it is combined with Phenobarbital.
PiroxicamThe metabolism of Piroxicam can be increased when combined with Phenobarbital.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Phenobarbital.
PizotifenThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Phenobarbital can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be increased when combined with Phenobarbital.
PolythiazidePhenobarbital may increase the orthostatic hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Phenobarbital.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Phenobarbital.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Phenobarbital.
PonatinibThe serum concentration of Phenobarbital can be increased when it is combined with Ponatinib.
PosaconazoleThe metabolism of Posaconazole can be increased when combined with Phenobarbital.
PosaconazoleThe serum concentration of Phenobarbital can be increased when it is combined with Posaconazole.
PractololThe serum concentration of Practolol can be decreased when it is combined with Phenobarbital.
PramipexolePhenobarbital may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pramocaine.
PrasugrelThe metabolism of Prasugrel can be increased when combined with Phenobarbital.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Phenobarbital.
PravastatinThe serum concentration of Phenobarbital can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Prazepam.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Phenobarbital.
PrazosinPhenobarbital may increase the hypotensive activities of Prazosin.
PrazosinThe serum concentration of Phenobarbital can be increased when it is combined with Prazosin.
PrednicarbateThe serum concentration of Prednicarbate can be decreased when it is combined with Phenobarbital.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Phenobarbital.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Phenobarbital.
PrednisoneThe serum concentration of Phenobarbital can be increased when it is combined with Prednisone.
PregabalinThe metabolism of Pregabalin can be increased when combined with Phenobarbital.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Phenobarbital.
PregnenoloneThe serum concentration of Pregnenolone can be decreased when it is combined with Phenobarbital.
PrenylamineThe metabolism of Prenylamine can be increased when combined with Phenobarbital.
PrilocaineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Prilocaine.
PrimaquineThe metabolism of Primaquine can be increased when combined with Phenobarbital.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Phenobarbital.
ProbenecidThe serum concentration of Phenobarbital can be increased when it is combined with Probenecid.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Phenobarbital.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenobarbital.
ProgesteroneThe serum concentration of Phenobarbital can be decreased when it is combined with Progesterone.
ProguanilThe metabolism of Proguanil can be increased when combined with Phenobarbital.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Phenobarbital.
PromethazineThe serum concentration of Phenobarbital can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Promethazine.
PropacetamolThe metabolism of Propacetamol can be increased when combined with Phenobarbital.
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Phenobarbital.
PropafenoneThe serum concentration of Phenobarbital can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Phenobarbital.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Phenobarbital.
PropoxycaineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Propoxycaine.
PropranololPhenobarbital may increase the hypotensive activities of Propranolol.
PropranololThe serum concentration of Phenobarbital can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Phenobarbital can be increased when it is combined with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Phenobarbital is combined with PSD502.
PyrazinamideThe metabolism of Pyrazinamide can be increased when combined with Phenobarbital.
PyridoxineThe metabolism of Phenobarbital can be increased when combined with Pyridoxine.
PyrimethamineThe metabolism of Phenobarbital can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Quazepam.
QuercetinThe serum concentration of Phenobarbital can be increased when it is combined with Quercetin.
QuetiapinePhenobarbital may increase the hypotensive activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenobarbital.
QuinacrineThe metabolism of Quinacrine can be increased when combined with Phenobarbital.
QuinacrineThe serum concentration of Phenobarbital can be increased when it is combined with Quinacrine.
QuinaprilPhenobarbital may increase the hypotensive activities of Quinapril.
QuinethazonePhenobarbital may increase the orthostatic hypotensive activities of Quinethazone.
QuinidinePhenobarbital may increase the hepatotoxic activities of Quinidine.
QuinidineThe serum concentration of Phenobarbital can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Phenobarbital.
QuinineThe serum concentration of Phenobarbital can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be increased when combined with Phenobarbital.
RaloxifeneThe metabolism of Raloxifene can be increased when combined with Phenobarbital.
RamelteonThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ramelteon.
RamiprilPhenobarbital may increase the hypotensive activities of Ramipril.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Phenobarbital.
RanitidineThe serum concentration of Phenobarbital can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Phenobarbital can be increased when it is combined with Ranolazine.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Phenobarbital.
RasagilineThe metabolism of Rasagiline can be increased when combined with Phenobarbital.
ReboxetineThe metabolism of Reboxetine can be increased when combined with Phenobarbital.
ReboxetineThe serum concentration of Phenobarbital can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Phenobarbital.
RegorafenibThe serum concentration of Phenobarbital can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenobarbital.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Phenobarbital.
RepaglinideThe metabolism of Repaglinide can be increased when combined with Phenobarbital.
ReserpinePhenobarbital may increase the hypotensive activities of Reserpine.
ReserpineThe serum concentration of Phenobarbital can be decreased when it is combined with Reserpine.
ResveratrolThe metabolism of Resveratrol can be increased when combined with Phenobarbital.
RetapamulinThe metabolism of Retapamulin can be increased when combined with Phenobarbital.
RifabutinThe metabolism of Rifabutin can be increased when combined with Phenobarbital.
RifampicinThe serum concentration of Phenobarbital can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Phenobarbital can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Phenobarbital.
RilpivirineThe serum concentration of Phenobarbital can be increased when it is combined with Rilpivirine.
RiluzoleThe metabolism of Riluzole can be increased when combined with Phenobarbital.
RimexoloneThe serum concentration of Rimexolone can be decreased when it is combined with Phenobarbital.
RimonabantThe metabolism of Rimonabant can be increased when combined with Phenobarbital.
RiociguatPhenobarbital may increase the hypotensive activities of Riociguat.
RisedronateThe metabolism of Risedronate can be increased when combined with Phenobarbital.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Phenobarbital.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Phenobarbital.
RitonavirThe serum concentration of Phenobarbital can be decreased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Phenobarbital.
RizatriptanThe metabolism of Rizatriptan can be increased when combined with Phenobarbital.
RofecoxibThe metabolism of Rofecoxib can be increased when combined with Phenobarbital.
RoflumilastThe serum concentration of Roflumilast can be decreased when it is combined with Phenobarbital.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Phenobarbital.
RolapitantThe serum concentration of Phenobarbital can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Phenobarbital.
RomifidineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Romifidine.
RopinirolePhenobarbital may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Phenobarbital.
RosiglitazoneThe metabolism of Rosiglitazone can be increased when combined with Phenobarbital.
RosuvastatinThe metabolism of Rosuvastatin can be increased when combined with Phenobarbital.
RotigotinePhenobarbital may increase the sedative activities of Rotigotine.
RoxithromycinThe metabolism of Roxithromycin can be increased when combined with Phenobarbital.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Phenobarbital.
RuxolitinibThe metabolism of Ruxolitinib can be increased when combined with Phenobarbital.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Phenobarbital is combined with S-Ethylisothiourea.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Phenobarbital.
SalmeterolThe metabolism of Salmeterol can be increased when combined with Phenobarbital.
SaquinavirThe serum concentration of Phenobarbital can be decreased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Phenobarbital.
ScopolamineThe serum concentration of Phenobarbital can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Phenobarbital.
SelegilineThe metabolism of Selegiline can be increased when combined with Phenobarbital.
SelegilineThe serum concentration of Phenobarbital can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Phenobarbital.
SeratrodastThe metabolism of Seratrodast can be increased when combined with Phenobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sertraline.
SertralineThe serum concentration of Phenobarbital can be increased when it is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sevoflurane.
SibutramineThe metabolism of Sibutramine can be increased when combined with Phenobarbital.
SildenafilThe metabolism of Sildenafil can be increased when combined with Phenobarbital.
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Phenobarbital.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Phenobarbital.
SimeprevirThe serum concentration of Phenobarbital can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be increased when combined with Phenobarbital.
SimvastatinThe serum concentration of Phenobarbital can be increased when it is combined with Simvastatin.
SirolimusThe metabolism of Sirolimus can be increased when combined with Phenobarbital.
SirolimusThe serum concentration of Phenobarbital can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Phenobarbital.
SitaxentanThe metabolism of Sitaxentan can be increased when combined with Phenobarbital.
Sodium NitriteThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sodium Nitrite.
Sodium oxybateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Phenobarbital.
SolifenacinThe metabolism of Solifenacin can be increased when combined with Phenobarbital.
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Phenobarbital.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Phenobarbital.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Phenobarbital.
SorafenibThe serum concentration of Phenobarbital can be increased when it is combined with Sorafenib.
SotalolPhenobarbital may increase the hypotensive activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Phenobarbital.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Phenobarbital.
SpiramycinThe metabolism of Spiramycin can be increased when combined with Phenobarbital.
SpironolactonePhenobarbital may increase the hypotensive activities of Spironolactone.
SpironolactoneThe serum concentration of Phenobarbital can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Phenobarbital can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Phenobarbital can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Stiripentol can be decreased when it is combined with Phenobarbital.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Phenobarbital.
StreptozocinThe serum concentration of Phenobarbital can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Phenobarbital.
SulfadiazineThe metabolism of Sulfadiazine can be increased when combined with Phenobarbital.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be increased when combined with Phenobarbital.
SulfamoxoleThe metabolism of Sulfamoxole can be increased when combined with Phenobarbital.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be increased when combined with Phenobarbital.
SulfinpyrazoneThe serum concentration of Phenobarbital can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Sulfisoxazole can be increased when combined with Phenobarbital.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Phenobarbital.
SumatriptanThe serum concentration of Phenobarbital can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Phenobarbital.
SunitinibThe serum concentration of Phenobarbital can be increased when it is combined with Sunitinib.
SuprofenThe metabolism of Suprofen can be increased when combined with Phenobarbital.
SuvorexantThe serum concentration of Suvorexant can be decreased when it is combined with Phenobarbital.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Phenobarbital.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be increased when combined with Phenobarbital.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Phenobarbital.
TacrineThe serum concentration of Phenobarbital can be increased when it is combined with Tacrine.
TacrineThe metabolism of Tacrine can be increased when combined with Phenobarbital.
TacrolimusThe serum concentration of Phenobarbital can be decreased when it is combined with Tacrolimus.
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Phenobarbital.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Phenobarbital.
TamsulosinThe metabolism of Tamsulosin can be increased when combined with Phenobarbital.
TapentadolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tapentadol.
TasimelteonThe serum concentration of Tasimelteon can be decreased when it is combined with Phenobarbital.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Phenobarbital.
TasosartanThe metabolism of Tasosartan can be increased when combined with Phenobarbital.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be increased when combined with Phenobarbital.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Phenobarbital.
Taurocholic AcidThe serum concentration of Phenobarbital can be increased when it is combined with Taurocholic Acid.
TazaroteneThe metabolism of Tazarotene can be increased when combined with Phenobarbital.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Phenobarbital.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Phenobarbital.
TelithromycinThe metabolism of Telithromycin can be increased when combined with Phenobarbital.
TelmisartanPhenobarbital may increase the hypotensive activities of Telmisartan.
TelmisartanThe serum concentration of Phenobarbital can be increased when it is combined with Telmisartan.
TemafloxacinThe metabolism of Temafloxacin can be increased when combined with Phenobarbital.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Phenobarbital.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Phenobarbital.
TemsirolimusThe serum concentration of Phenobarbital can be increased when it is combined with Temsirolimus.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Phenobarbital.
TenoxicamThe metabolism of Tenoxicam can be increased when combined with Phenobarbital.
TerazosinPhenobarbital may increase the hypotensive activities of Terazosin.
TerazosinThe serum concentration of Phenobarbital can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be increased when combined with Phenobarbital.
TerfenadineThe metabolism of Terfenadine can be increased when combined with Phenobarbital.
TerfenadineThe serum concentration of Phenobarbital can be increased when it is combined with Terfenadine.
TesmilifeneThe metabolism of Tesmilifene can be increased when combined with Phenobarbital.
TesmilifeneThe serum concentration of Phenobarbital can be decreased when it is combined with Tesmilifene.
TestosteroneThe metabolism of Testosterone can be increased when combined with Phenobarbital.
TestosteroneThe serum concentration of Phenobarbital can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tetracaine.
TetracyclineThe metabolism of Tetracycline can be increased when combined with Phenobarbital.
TetrodotoxinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tetrodotoxin.
ThalidomidePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Phenobarbital.
TheobromineThe metabolism of Theobromine can be increased when combined with Phenobarbital.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Phenobarbital.
ThiabendazoleThe metabolism of Thiabendazole can be increased when combined with Phenobarbital.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Phenobarbital.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Phenobarbital.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Phenobarbital.
ThiotepaThe metabolism of Thiotepa can be increased when combined with Phenobarbital.
ThiothixeneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tiagabine.
TianeptineThe metabolism of Tianeptine can be increased when combined with Phenobarbital.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Phenobarbital resulting in a loss in efficacy.
TicagrelorThe serum concentration of Phenobarbital can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Ticlopidine can be increased when combined with Phenobarbital.
TiletamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tiletamine.
TimololPhenobarbital may increase the hypotensive activities of Timolol.
TinidazoleThe metabolism of Tinidazole can be increased when combined with Phenobarbital.
TiotropiumThe metabolism of Tiotropium can be increased when combined with Phenobarbital.
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Phenobarbital.
TixocortolThe serum concentration of Tixocortol can be decreased when it is combined with Phenobarbital.
TizanidinePhenobarbital may increase the hypotensive activities of Tizanidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Phenobarbital.
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Phenobarbital.
TolbutamideThe metabolism of Tolbutamide can be increased when combined with Phenobarbital.
TolcaponeThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tolcapone.
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Phenobarbital.
TolterodineThe metabolism of Tolterodine can be increased when combined with Phenobarbital.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Phenobarbital.
TolvaptanThe serum concentration of Phenobarbital can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Phenobarbital.
TorasemidePhenobarbital may increase the hypotensive activities of Torasemide.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Phenobarbital.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Phenobarbital.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Phenobarbital.
TrandolaprilPhenobarbital may increase the hypotensive activities of Trandolapril.
TranilastThe metabolism of Tranilast can be increased when combined with Phenobarbital.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenobarbital.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Phenobarbital.
TrazodoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Trazodone.
TrazodoneThe serum concentration of Phenobarbital can be decreased when it is combined with Trazodone.
TreprostinilThe serum concentration of Treprostinil can be decreased when it is combined with Phenobarbital.
TretinoinThe metabolism of Tretinoin can be increased when combined with Phenobarbital.
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Phenobarbital.
TriamterenePhenobarbital may increase the hypotensive activities of Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Phenobarbital.
TrichlormethiazidePhenobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
TrifluoperazineThe serum concentration of Phenobarbital can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Phenobarbital can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be increased when combined with Phenobarbital.
TrimethoprimThe metabolism of Trimethoprim can be increased when combined with Phenobarbital.
TrimethoprimThe serum concentration of Phenobarbital can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Phenobarbital can be increased when it is combined with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Triprolidine.
TroglitazoneThe metabolism of Troglitazone can be increased when combined with Phenobarbital.
TroleandomycinThe metabolism of Troleandomycin can be increased when combined with Phenobarbital.
TroleandomycinThe serum concentration of Phenobarbital can be increased when it is combined with Troleandomycin.
UdenafilThe metabolism of Udenafil can be increased when combined with Phenobarbital.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Phenobarbital.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Phenobarbital.
ValdecoxibThe metabolism of Valdecoxib can be increased when combined with Phenobarbital.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Phenobarbital.
ValsartanPhenobarbital may increase the hypotensive activities of Valsartan.
ValsartanThe metabolism of Phenobarbital can be decreased when combined with Valsartan.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Phenobarbital.
VanoxerineThe metabolism of Vanoxerine can be increased when combined with Phenobarbital.
VardenafilThe metabolism of Vardenafil can be increased when combined with Phenobarbital.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Phenobarbital.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Phenobarbital.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Phenobarbital.
VenlafaxineThe serum concentration of Phenobarbital can be increased when it is combined with Venlafaxine.
VerapamilPhenobarbital may increase the hypotensive activities of Verapamil.
VerapamilThe serum concentration of Phenobarbital can be decreased when it is combined with Verapamil.
VicrivirocThe metabolism of Vicriviroc can be increased when combined with Phenobarbital.
VigabatrinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Vigabatrin.
VilanterolThe metabolism of Vilanterol can be increased when combined with Phenobarbital.
VilazodoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Phenobarbital.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Phenobarbital.
VindesineThe metabolism of Vindesine can be increased when combined with Phenobarbital.
VinorelbineThe metabolism of Vinorelbine can be increased when combined with Phenobarbital.
VinorelbineThe serum concentration of Phenobarbital can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Phenobarbital.
VorapaxarThe serum concentration of Vorapaxar can be decreased when it is combined with Phenobarbital.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Phenobarbital.
VoriconazoleThe metabolism of Phenobarbital can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Vortioxetine.
WarfarinThe metabolism of Warfarin can be increased when combined with Phenobarbital.
XimelagatranThe metabolism of Ximelagatran can be increased when combined with Phenobarbital.
XylazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Xylazine.
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Phenobarbital.
YohimbineThe metabolism of Yohimbine can be increased when combined with Phenobarbital.
ZafirlukastThe metabolism of Zafirlukast can be increased when combined with Phenobarbital.
ZalcitabineThe metabolism of Zalcitabine can be increased when combined with Phenobarbital.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Phenobarbital.
ZaltoprofenThe metabolism of Zaltoprofen can be increased when combined with Phenobarbital.
ZiconotideThe metabolism of Ziconotide can be increased when combined with Phenobarbital.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Phenobarbital.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Phenobarbital.
ZileutonThe metabolism of Zileuton can be increased when combined with Phenobarbital.
ZimelidineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Zimelidine.
ZimelidineThe serum concentration of Phenobarbital can be increased when it is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Phenobarbital.
ZolazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Zolazepam.
ZolmitriptanThe metabolism of Zolmitriptan can be increased when combined with Phenobarbital.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Phenobarbital.
ZomepiracThe metabolism of Zomepirac can be increased when combined with Phenobarbital.
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Phenobarbital.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Phenobarbital.
ZopicloneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Zotepine.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be decreased when it is combined with Phenobarbital.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Phenobarbital.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.
  • Take on an empty stomach for quicker absorption

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  5. Macdonald RL, McLean MJ: Anticonvulsant drugs: mechanisms of action. Adv Neurol. 1986;44:713-36. [PubMed:2871724 ]
  6. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  7. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  3. Jin LJ, Schlesinger F, Song YP, Dengler R, Krampfl K: The interaction of the neuroprotective compounds riluzole and phenobarbital with AMPA-type glutamate receptors: a patch-clamp study. Pharmacology. 2010;85(1):54-62. doi: 10.1159/000268641. Epub 2009 Dec 23. [PubMed:20051697 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
Components:
NameUniProt IDDetails
Glutamate receptor ionotropic, NMDA 1Q05586 Details
Glutamate receptor ionotropic, NMDA 2AQ12879 Details
Glutamate receptor ionotropic, NMDA 2BQ13224 Details
Glutamate receptor ionotropic, NMDA 2CQ14957 Details
Glutamate receptor ionotropic, NMDA 2DO15399 Details
Glutamate receptor ionotropic, NMDA 3AQ8TCU5 Details
Glutamate receptor ionotropic, NMDA 3BO60391 Details
References
  1. Daniell LC: Effect of anesthetic and convulsant barbiturates on N-methyl-D-aspartate receptor-mediated calcium flux in brain membrane vesicles. Pharmacology. 1994 Nov;49(5):296-307. [PubMed:7862741 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A: Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003 Apr;31(4):421-31. [PubMed:12642468 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Kawalek JC, Howard KD, Farrell DE, Derr J, Cope CV, Jackson JD, Myers MJ: Effect of oral administration of low doses of pentobarbital on the induction of cytochrome P450 isoforms and cytochrome P450-mediated reactions in immature Beagles. Am J Vet Res. 2003 Sep;64(9):1167-75. [PubMed:13677397 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Kawalek JC, Howard KD, Farrell DE, Derr J, Cope CV, Jackson JD, Myers MJ: Effect of oral administration of low doses of pentobarbital on the induction of cytochrome P450 isoforms and cytochrome P450-mediated reactions in immature Beagles. Am J Vet Res. 2003 Sep;64(9):1167-75. [PubMed:13677397 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. von Bahr C, Steiner E, Koike Y, Gabrielsson J: Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism. Clin Pharmacol Ther. 1998 Jul;64(1):18-26. [PubMed:9695715 ]
  3. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol. 1999 Jun;39(6):567-77. [PubMed:10354960 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Sakuma T, Ohtake M, Katsurayama Y, Jarukamjorn K, Nemoto N: Induction of CYP1A2 by phenobarbital in the livers of aryl hydrocarbon-responsive and -nonresponsive mice. Drug Metab Dispos. 1999 Mar;27(3):379-84. [PubMed:10064569 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Kawalek JC, Howard KD, Farrell DE, Derr J, Cope CV, Jackson JD, Myers MJ: Effect of oral administration of low doses of pentobarbital on the induction of cytochrome P450 isoforms and cytochrome P450-mediated reactions in immature Beagles. Am J Vet Res. 2003 Sep;64(9):1167-75. [PubMed:13677397 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Leukotriene-b4 20-monooxygenase activity
Specific Function:
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).
Gene Name:
CYP4A11
Uniprot ID:
Q02928
Molecular Weight:
59347.31 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP4B1
Uniprot ID:
P13584
Molecular Weight:
58990.64 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764 ]
  2. Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75. doi: 10.1016/j.neuropharm.2008.08.032. Epub 2008 Sep 11. [PubMed:18824002 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Kiuchi Y, Suzuki H, Hirohashi T, Tyson CA, Sugiyama Y: cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 1998 Aug 14;433(1-2):149-52. [PubMed:9738950 ]
  2. Cherrington NJ, Slitt AL, Maher JM, Zhang XX, Zhang J, Huang W, Wan YJ, Moore DD, Klaassen CD: Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor. Drug Metab Dispos. 2003 Nov;31(11):1315-9. [PubMed:14570762 ]
  3. Slitt AL, Cherrington NJ, Maher JM, Klaassen CD: Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites. Drug Metab Dispos. 2003 Sep;31(9):1176-86. [PubMed:12920174 ]
  4. Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, Akizawa T, Yoshioka M, Sugiyama Y: Characterization of inducible nature of MRP3 in rat liver. Am J Physiol Gastrointest Liver Physiol. 2000 Mar;278(3):G438-46. [PubMed:10712264 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA: Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002 Jan 25;277(4):2908-15. Epub 2001 Nov 12. [PubMed:11706036 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Kiuchi Y, Suzuki H, Hirohashi T, Tyson CA, Sugiyama Y: cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 1998 Aug 14;433(1-2):149-52. [PubMed:9738950 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A.
Gene Name:
SLCO2A1
Uniprot ID:
Q92959
Molecular Weight:
70043.33 Da
References
  1. Hagenbuch N, Reichel C, Stieger B, Cattori V, Fattinger KE, Landmann L, Meier PJ, Kullak-Ublick GA: Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver. J Hepatol. 2001 Jun;34(6):881-7. [PubMed:11451172 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Courtois A, Payen L, Le Ferrec E, Scheffer GL, Trinquart Y, Guillouzo A, Fardel O: Differential regulation of multidrug resistance-associated protein 2 (MRP2) and cytochromes P450 2B1/2 and 3A1/2 in phenobarbital-treated hepatocytes. Biochem Pharmacol. 2002 Jan 15;63(2):333-41. [PubMed:11841808 ]
  2. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161 ]
  3. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA: Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002 Jan 25;277(4):2908-15. Epub 2001 Nov 12. [PubMed:11706036 ]
  4. Kauffmann HM, Schrenk D: Sequence analysis and functional characterization of the 5'-flanking region of the rat multidrug resistance protein 2 (mrp2) gene. Biochem Biophys Res Commun. 1998 Apr 17;245(2):325-31. [PubMed:9571149 ]
  5. Johnson DR, Habeebu SS, Klaassen CD: Increase in bile flow and biliary excretion of glutathione-derived sulfhydryls in rats by drug-metabolizing enzyme inducers is mediated by multidrug resistance protein 2. Toxicol Sci. 2002 Mar;66(1):16-26. [PubMed:11861969 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23